Posted On: 09/02/2014 12:28:30 AM
Post# of 30015
![Avatar](https://investorshangout.com/images/ProfileImages/1995814672_12871_thHEULNIV0.jpg)
Just a reminder about todays update after the close.
The Company will host a business update call on September 2, 2014 at 4:15 PM ET. To participate please dial 877-737-7051, (international dialers 201-689-8878), Participant Passcode: 2027916. The Company anticipates addressing a number of matters related to our core programs, including qualitative early revenue guidance for LymPro, progress being made on the Company's Phase 2b initiation with Eltoprazine for PD LID, and next steps toward a first-in-man trial for MANF in orphan ophthalmological indications. You may pre-register at: http://services.incommconferencing.com/Diamon...g=3099c1ec
"The Company is now on firmer financial footing than it has historically been, with access to flexible financing due to our agreement with Lincoln Park Capital and the successful retirement of significant derivative liability," said Robert Farrell, J.D., Chief Financial Officer of Amarantus. "Going forward, we anticipate an increase in expenditures due to research and development activities of our key programs. We have access to the necessary resources to fund these activities. In addition, we are currently exploring various strategies to offset certain of these expenditures as prudently and deliberately as possible as we continue to build Amarantus towards a listing on a national exchange in the near future."
Bring it on Gerald and the new team!
The Company will host a business update call on September 2, 2014 at 4:15 PM ET. To participate please dial 877-737-7051, (international dialers 201-689-8878), Participant Passcode: 2027916. The Company anticipates addressing a number of matters related to our core programs, including qualitative early revenue guidance for LymPro, progress being made on the Company's Phase 2b initiation with Eltoprazine for PD LID, and next steps toward a first-in-man trial for MANF in orphan ophthalmological indications. You may pre-register at: http://services.incommconferencing.com/Diamon...g=3099c1ec
"The Company is now on firmer financial footing than it has historically been, with access to flexible financing due to our agreement with Lincoln Park Capital and the successful retirement of significant derivative liability," said Robert Farrell, J.D., Chief Financial Officer of Amarantus. "Going forward, we anticipate an increase in expenditures due to research and development activities of our key programs. We have access to the necessary resources to fund these activities. In addition, we are currently exploring various strategies to offset certain of these expenditures as prudently and deliberately as possible as we continue to build Amarantus towards a listing on a national exchange in the near future."
Bring it on Gerald and the new team!
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)